Community Practice Connections™: MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

This interactive, case-based online activity features commentary from leading clinical experts in MPN treatment: Ronald Hoffman, MD; Rami S. Komrokji, MD; Ann Mullally, MD; and Abdulraheem Yacoub, MD. Topics include the impact of histologic and molecular patient characteristics on treatment decision making, JAK-STAT inhibition and interferon therapy as clinical strategies, and a look at the evolving therapeutic landscape for patients with myeloproliferative neoplasms‎ (MPNs). Specifically, clinical cases examining appropriate treatment options for patients with varying degrees of risk with polycythemia vera (PV) and myelofibrosis (MF) are presented. The latest data from clinical trials investigating emerging agents and combination strategies across MPNs are applied to faculty discussion of pertinent clinical cases.

Benefits of Participating

• Update your clinical approach through a discussion of the most up-to-date risk-scoring systems for MPNs in patients with varying risk levels
• Review best practices for management of patients with MPNs
• Learn how to evaluate patients for referral to clinical trials
• Hear top experts develop appropriate treatment plans for a variety of patients with MPNs

Acknowledgement of Commercial Support

This activity is supported by educational grants from CTI BioPharma Corp, Incyte Corporation, and PharmaEssentia USA.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with MPNs. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other healthcare professionals interested in the treatment of cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Review recent updates in molecular diagnostics and their potential impact on clinical decision making in the management of MF and PV
• Explain the mechanistic rationale for overlap of MF and PV therapeutic approaches in the context of the current treatment landscape
• Assess data from recent clinical trials on emerging strategies for the treatment of MF and PV
• Discuss strategies to integrate recent trial findings into clinical practice to optimize decision making and care for patients with MF and PV

Faculty, Staff, and Planners’ Disclosures

Faculty

Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Director, Myeloproliferative Disorders Research Program
Tisch Cancer Institute
Mount Sinai School of Medicine
New York, NY

Disclosures: no relevant financial relationships with commercial interests.

Rami S. Komrokji, MD
Senior Member
Section Head, Leukemia & MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL

Disclosures: Consultant: Agios Pharmaceuticals; Celgene; Daiichi Sankyo, Inc; Geron Corporation; Incyte Corporation; Pfizer; Jazz Pharmaceuticals; Novartis; Speakers Bureau: Alexion Pharmaceuticals, Jazz Pharmaceuticals, Novartis; Shareholder: Avidity Biosciences, C4 Therapeutics, Fount Therapeutics, nRichDx, Revolution Medicines.

Ann Mullally, MD
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Janssen Pharmaceuticals; Speakers Bureau: Incyte Corporation, Roche.

Abdulraheem Yacoub, MD
Associate Professor of Medicine
Clinical Director of Ambulatory Hematology Clinics
University of Kansas Medical Center
Kansas City, KS

Disclosures: Speakers Bureau: Incyte Corporation, Novartis, Agios Pharmaceuticals, Seattle Genetics; Shareholder: Ardelyx; Dynnana; HylaPharm, LLC; Cara Therapeutics.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER^® or the company that provided commercial support for this activity.